SAREPTA THERAPEUTICS INC's gross profit margin for the first quarter of its fiscal year 2015 has significantly increased when compared to the same period a year ago. Sales and net income fell significantly, underperforming compared to the average company in its industry. SAREPTA THERAPEUTICS INC is extremely liquid. Currently, the Quick Ratio is 4.97 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.
During the same period, stockholders' equity ("net worth") has decreased by 12.31% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY15||Q1 FY14|
|Net Sales ($mil)||0.0||6.09|
|Net Income ($mil)||-61.56||-28.27|
|Balance Sheet||Q1 FY15||Q1 FY14|
|Cash & Equiv. ($mil)||166.22||232.44|
|Total Assets ($mil)||242.71||275.39|
|Total Debt ($mil)||6.38||1.65|
|Profitability||Q1 FY15||Q1 FY14|
|Gross Profit Margin||0.0||-403.89|
|Return on Assets||-69.66||-35.64|
|Return on Equity||-84.21||-42.87|
|Debt||Q1 FY15||Q1 FY14|
|Share Data||Q1 FY15||Q1 FY14|
|Shares outstanding (mil)||41.35||37.99|
|Div / share||0.0||0.0|
|Book value / share||4.85||6.03|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1304187.0||1048646.0|
SELL. This stock?s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. To use another comparison, its price-to-book ratio of 5.00 indicates a significant premium versus the S&P 500 average of 2.88 and a significant discount versus the industry average of 11.28. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, SAREPTA THERAPEUTICS INC proves to trade at a discount to investment alternatives within the industry.
|SRPT NM||Peers 56.92||SRPT NM||Peers 49.52|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
SRPT's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
SRPT's P/CF is negative making the measure meaningless.
|SRPT NM||Peers 61.05||SRPT NA||Peers 0.64|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
SRPT's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|SRPT 5.00||Peers 11.28||SRPT -46.45||Peers 32.33|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
SRPT is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, SRPT is expected to significantly trail its peers on the basis of its earnings growth rate.
|SRPT 273.36||Peers 343.48||SRPT -76.83||Peers 283.43|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
SRPT is trading at a discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
SRPT significantly trails its peers on the basis of sales growth
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV